CORRESP

REGENXBIO Inc.

9600 Blackwell Road, Suite 210

Rockville, MD 20850

January 4, 2017

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

Attention: Mary Beth Breslin

 

Re: REGENXBIO Inc.

Registration Statement on Form S-3 (File No. 333-215146)

Dear Ms. Breslin:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, REGENXBIO Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 5:00 p.m. Eastern Time on Friday, January 6, 2017 or as soon thereafter as practicable.

The Company hereby authorizes Albert Vanderlaan of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

Please provide a copy of the Commission’s order declaring the Registration Statement effective to Albert Vanderlaan at Gunderson Dettmer, One Marina Park Drive, Suite 900, Boston, MA 02210. If possible, please also send such order by email to the attention of Albert Vanderlaan at avanderlaan@gunder.com.

Thank you for your attention on this matter.

 

Very truly yours,
REGENXBIO Inc.
By:  

/s/ Kenneth T. Mills

  Kenneth T. Mills
  President and Chief Executive Officer

 

cc: Patrick Christmas, REGENXBIO Inc.

Jay Hachigian, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

Keith Scherer, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

Albert Vanderlaan, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP